Viewing data from:

PRIMIDONE

ANDA

PRIMIDONE | A218366 | CARNEGIE PHARMACEUTICALS LLC

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: MYSOLINE(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 3 NDCs

Highest NADAC/Unit

$0.2237

per ea

Lowest NADAC/Unit

$0.0924

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
80005011811PRIMIDONE 250 MG TABLET	$0.2237	EA	Generic	—	2026-10-21
80005011711PRIMIDONE 50 MG TABLET	$0.0924	EA	Generic	—	2026-10-21
80005011714PRIMIDONE 50 MG TABLET	$0.0924	EA	Generic	—	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 3 NDCs (3 FSS)

Lowest Price

$7.24

Highest Price

$27.40

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
80005-0117-11PRIMIDONE 50MG TAB	$7.24	FSS	First Nation Group, LLC	09/14/2029
80005-0117-14PRIMIDONE 50MG TAB	$27.40	FSS	First Nation Group, LLC	09/14/2029
80005-0118-11PRIMIDONE 250MG TAB	$17.99	FSS	First Nation Group, LLC	09/14/2029

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain5 active DMFs2 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

SIEGFRIED LTDPRIMIDONE

DMF 21991973

DR REDDYS LABORATORIES LTDPRIMIDONE

DMF 200072006

NANTONG JINGHUA PHARMACEUTICAL CO LTDPRIMIDONE

DMF 216022008

BIOPHORE INDIA PHARMACEUTICALS PVT LTDPRIMIDONE

DMF 352022020

RAKS PHARMA PVT LTDPRIMIDONE USP

DMF 407702024

NANTONG GENERAL PHARMACEUTICAL FACTORYInactivePRIMIDONE USP XXII

DMF 84061990

PROVENTUS LIFE SCIENCES PVT LTDInactivePRIMIDONE

DMF 234442010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 50MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jan 23, 2024

No patent or exclusivity listings for this strength.

#002 — 250MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 23, 2024